Roche’s Tecentriq in Combination with Exelixis’s Cabometyx Meets Primary Endpoint in mCRPC Phase III Study
Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced positive results from a Phase III...
Clinical trial results
Eli Lilly’s Subsidiary Akouos Reports Positive Preliminary Results for Gene Therapy in Hearing Loss
Eli Lilly (NYSE: LLY) has announced preliminary results from a Phase I/II study conducted by...
BMS’s Opdivo-Yervoy Combo Cuts Cancer Progression Risk by 79% in Phase III Study
Bristol Myers Squibb (BMS; NYSE: BMY) has published late-stage and long-term data for its anti-PD-1...
Merck’s Bavencio Shows Promising Survival Data in Real-World Urothelial Carcinoma Studies
German pharmaceutical company Merck (NYSE: MRK) has released data from real-world studies for its anti-PD-L1...
Gilead’s Trodelvy Misses Primary Endpoint in Late-Stage NSCLC Trial
Gilead Sciences (NASDAQ: GILD) has announced that a late-stage trial for its antibody-drug conjugate (ADC)...
Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced preliminary results from a Phase III study...
AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint...
CARsgen Therapeutics’ CT041 Shows Promising Results in Advanced Solid Tumors at ASCO GI 2024
China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the presentation of...
Eisai and Medivir’s Combo Therapy Advances in Liver Cancer with Positive Trial Results
Japanese pharmaceutical company Eisai’s (TYO: 4523) kinase inhibitor Lenvima (Lenvatinib), combined with Swedish partner Medivir’s...
Regenxbio’s One-Time Gene Therapy for Wet AMD Shows Promise in Phase II Study
Gene therapy specialist Regenxbio (NASDAQ: RGNX) has announced preliminary results from a Phase II study...
Novo Nordisk’s IcoSema Shows Promise in Late-Stage Trial for Type 2 Diabetes Management
Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial...
AbbVie’s Lutikizumab Advances to Phase III for Hidradenitis Suppurativa After Positive Mid-Stage Results
AbbVie (NYSE: ABBV) has announced the progression of lutikizumab to Phase III clinical trials following...
Ascletis Pharma’s ASC41 Shows Promising Results in Phase II NASH Study
Ascletis Pharma Inc. (HKG: 1672), a Chinese pharmaceutical company, has announced positive interim results from...
Jiangsu Recbio’s REC610 Shingles Vaccine Shows Positive Results in First-In-Human Study
Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a Chinese biotechnology company, has announced positive results...
Clover Biopharma’s SCB-219M Shows Promising Phase I Results for Chemotherapy-Induced Thrombocytopenia
Clover Biopharmaceuticals Ltd (HKG: 2197), based in China, has announced promising preliminary results from its...
AbbVie and Alpine Immune Sciences Halt Early Enrollment in Lupus Trial
AbbVie (NYSE: ABBV) and Alpine Immune Sciences (SWX: ALPN) have made the decision to prematurely...
Yifan Pharmaceutical’s F-652 Shows Promise in Phase II Clinical Trial for ACLF
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a China-based pharmaceutical company, has reported positive outcomes from...
Sanofi Halts Development of Tusamitamab Ravtansine After Missed Trial Endpoints
Sanofi (NASDAQ: SNY) has announced the discontinuation of its antibody-drug conjugate (ADC) tusamitamab ravtansine following...
Zylox-Tonbridge Completes Patient Enrollment for ZENFLEX Study in Germany
Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...
InnoCare’s TYK2 Inhibitor ICP-332 Shows Positive Results in Atopic Dermatitis Phase II Study
Beijing InnoCare Pharma Tech Co., (HKG: 9969), a Chinese biotechnology company specializing in oncology and...